BBBenjamin Bertin

Benjamin Bertin

*This is an algorithmically generated author record based on publicly available information.

Benjamin Bertin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Alain Combes

    Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation , Paris

    1 shared publication
  • Alban Redheuil

    Sorbonne University, Department of Cardiovascular and Thoracic Radiology, Hôpital de la Pitié-Salpêtrière (AP-HP), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; Sorbonne University, Biomedical Imaging Laboratory (LIB), INSERM, CNRS, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

    1 shared publication
  • Charles Juvin

    Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Chirurgie Cardio-Thoracique , Paris

    1 shared publication
  • Eric Vicaut

    AP-HP, Saint Louis/Lariboisière Hospitals, Unité de recherche clinique and Université Paris 7

    1 shared publication
  • Estelle Gandjbakhch

    Sorbonne Université, APHP, La Pitié Salpetrière University Hospital , Paris

    1 shared publication
  • Fleur Cohen Aubart

    Internal Medicine Department 2, French Referral Center for Histiocytoses Assistance Publique–Hôpitaux de Paris Pitié–Salpêtrière Hospital, Sorbonne Université, Paris, France

    1 shared publication

Latest Publications

  • Prognostic impact of pericardial effusion in patients with acute myocarditis

    by Matthieu Proust, Florent Huang, Michel Zeitouni, Nadjib Hammoudi, Marie Dupuy, Estelle Gandjbakhch, Philippe Charron, Alban Redheuil, Francesco Ravera, Benjamin Bertin, et al.

    Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.